EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti‐Drug Antibodies During Maintenance Therapy

Tore Grimstad iD, Arne Carlsen iD, Jan Terje Kvaløy, Nils Bolstad, David John Warren, Lars Aabakken, Knut E A Lundin, Lars Karlsen, Øyvind Steinsbø, Roald Omdal

Scandinavian Journal of Immunology · 2025

DOI: 10.1111/sji.70029 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Scandinavian Journal of Immunology, 2025. Verfasst von Tore Grimstad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway. Hauptthemen laut MEDLINE: Adalimumab, Colitis, Ulcerative, Crohn Disease, Fatigue. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several studies have shown that infliximab and adalimumab ameliorate fatigue in inflammatory bowel disease. We investigated whether serum levels of these agents above or below a selected threshold influence fatigue severity. In this cross‐sectional study, we measured serum concentrations (s‐) of infliximab and adalimumab and corresponding anti‐drug antibody levels. Therapeutic thresholds were defined as s‐infliximab ≥ 5.0 mg/L and s‐adalimumab ≥ 7.0 mg/L. Disease activity was assessed using the Harvey–Bradshaw Index for Crohn's disease, Partial Mayo Score for ulcerative colitis, and C‐reactive protein (CRP) and faecal calprotectin levels for both conditions. Fatigue was assessed with the Fatigue Visual Analog Scale and Fatigue Severity Scale, and depression was evaluated with the Hospital Anxiety and Depression Scale, Depression subscale. Of 171 included patients (112 with Crohn's disease, 59 with ulcerative colitis), 66 (38.6%) were on infliximab and 105 (61.4%) were on adalimumab. Scores on the two fatigue scales were similar for serum values above versus below therapeutic thresholds for both drugs and did not differ with versus without anti‐drug antibodies against either drug. CRP was numerically higher with infliximab levels below versus above the threshold ( p = 0.06), whereas both CRP and faecal calprotectin were increased with adalimumab below versus above the threshold ( p = 0.022, p = 0.0242). In patients with inflammatory bowel disease on maintenance therapy, s‐infliximab and s‐adalimumab levels below or above therapeutic thresholds or the presence of anti‐drug antibodies did not affect fatigue severity. Trial Registration: ClinicalTrials.gov identifier: NCT02134054

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabColitis, UlcerativeCrohn DiseaseFatigueInflammatory Bowel DiseasesInfliximabAdultAgedFemaleHumansMaleMiddle AgedAntibodiesC-Reactive ProteinCross-Sectional StudiesFecesLeukocyte L1 Antigen ComplexSeverity of Illness Index

Stichwörter der Autor:innen

fatigueinflammatory bowel diseaseserum drug level

Substanzen

AdalimumabAntibodiesC-Reactive ProteinInfliximabLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Gastroenterology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway.
  • Faculty of Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Research Department, Stavanger University Hospital, Stavanger, Norway.
  • Department of Mathematics and Physics, University of Stavanger, Stavanger, Norway.
  • Department of Medical Biochemistry, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
  • Department of Transplantation Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.

ORCID-Profile: Tore Grimstad, Arne Carlsen

Zitieren

APA

Grimstad, T., Carlsen, A., Kvaløy, J. T., Bolstad, N., Warren, D. J., Aabakken, L., Lundin, K. E. A., Karlsen, L., Steinsbø, Ø., & Omdal, R. (2025). Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti‐Drug Antibodies During Maintenance Therapy. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.70029

Vancouver

Grimstad T, Carlsen A, Kvaløy JT, Bolstad N, Warren DJ, Aabakken L, et al. Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti‐Drug Antibodies During Maintenance Therapy. Scandinavian Journal of Immunology. 2025. doi:10.1111/sji.70029

BibTeX
@article{Grimstad2025,
  author = {Grimstad, Tore and Carlsen, Arne and Kvaløy, Jan Terje and Bolstad, Nils and Warren, David John and Aabakken, Lars and Lundin, Knut E A and Karlsen, Lars and Steinsbø, Øyvind and Omdal, Roald},
  title = {Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti‐Drug Antibodies During Maintenance Therapy},
  journal = {Scandinavian Journal of Immunology},
  year = {2025},
  doi = {10.1111/sji.70029}
}
Kostenlos starten →